42 results on '"Zelenetz, Andrew"'
Search Results
2. Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era
3. Outcomes of primary refractory diffuse large B‐cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era
4. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types
5. The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months
6. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma
7. Supplement to: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
8. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era
9. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
10. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States
11. Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project
12. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation
13. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network
14. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era
15. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
16. Association of quantitative assessment of the intrafollicular proliferation index with outcome in follicular lymphoma
17. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database
18. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: A comprehensive analysis from the NCCN lymphoma outcomes project
19. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Findings from a large national database
20. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
21. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
22. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
23. A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma
24. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma
25. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
26. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma
27. Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia
28. Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies
29. Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkinʼs Lymphomas
30. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999
31. Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Detected by Clonotypic Polymerase Chain Reaction Despite Continuous Pathologic Remission Induced by Involved-Field Radiotherapy
32. Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkinʼs Lymphoma and Mantle Cell Lymphoma
33. Adverse prognostic significance of CD20 positive Reed–Sternberg cells in classical Hodgkinʼs disease
34. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkinʼs disease
35. Intensive Methotrexate and Cytarabine Followed by High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Newly Diagnosed Primary CNS Lymphoma: An Intent-to-Treat Analysis
36. Iodine-131 Tositumomab (Bexxar®) in Relapsed/Refractory Non-Hodgkinʼs Lymphoma: Update from the 2001 American Society of Hematology Meeting
37. Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
38. Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
39. A novel gene STORP (STOmatin-Related Protein) is localized 2 kb upstream of the promyelocytic gene on chromosome 15q22
40. Bone Marrow Transplantation versus Chemotherapy in Non-Hodgkin's Lymphoma
41. Bone Marrow Transplantation versus Chemotherapy in Non-Hodgkin's Lymphoma
42. Mucosa-Associated Lymphoid-Tissue Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.